Pulmonary Fibrosis: A Common Cause with Rheumatologists and Physicians
Surinder K. Jindal
Citation Information :
Jindal SK. Pulmonary Fibrosis: A Common Cause with Rheumatologists and Physicians. Indian J Chest Dis Allied Sci 2020; 62 (3):113-115.
Travis WD, Costabel U, Hansell DM, King TE Jr, Lynch DA, Nicholson AG, et al. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2013;188:733–48.
Dhooria S, Agarwal R, Dhar R, Jindal A, Madan K, Aggarwal AN, et al. Consensus statement for the diagnosis and treatment of idiopathic pulmonary fibrosis in resource constrained settings. Indian J Chest Dis Allied Sci 2018;60:93–121.
Fischer A, Strek M, Cottin V, Dellaripa P, Bernstein E, Brown K, et al. Proceedings of the American College of Rheumatology/Association of Physicians of Great Britain and Ireland Connective Tissue Disease–Associated Interstitial Lung Disease Summit: A Multidisciplinary Approach to Address Challenges and Opportunities. Arthritis Rheumatol 2019;71:pp 182–95.
Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. N Engl J Med 2009;360:1989–2003.
Solomon JJ, Olson AL, Fischer A, Bull T, Brown KK, Raghu G. Scleroderma lung disease. Eur Respir Rev 2013;22:6–19.
Kim EJ, Collard HR, King TE, Jr. Rheumatoid arthritisassociated interstitial lung disease: the relevance of histopathologic and radiographic pattern. Chest 2009;136:1397–1405.
Mathai S, Danoff S. Management of interstitial lung disease associated with connective tissue disease. Br Med J 2016;352:h6819.
Varone F, Inoue Y, Richeldi L. Twenty five years of respirology: advances in idiopathic pulmonary fibrosis. Respirology 2020;25:20–22.
Singh S, Sharma BB, Bairwa M, Gothi D, Desai U, Joshi JM, Talwar D, et al. Management of interstitial lung diseases: A consensus statement of the Indian Chest Society (ICS) and National College of Chest Physicians (NCCP). Lung India 2020;37:359–78.
Bradley B, Branley HM, Egan JJ, Greaves MS, Hansell DM, Harrison NK, et al. British Thoracic Society Interstitial Lung Disease Guideline Group, British Thoracic Society Standards of Care Committee; Thoracic Society of Australia; New Zealand Thoracic Society; Irish Thoracic Society Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society [published correction in Thorax 2008;63:1029]. Thorax 2008;63(Suppl. 5):v1-v58.
Vij R, Strek ME. Diagnosis and treatment of connective tissue disease-associated interstitial lung disease. Chest 2013;143:814–24.
Distler O, Highland KB, Gahlemann M, Azuma A, Fischer A, Mayes MD, et al. Nintedanib for systemic sclerosis–associated interstitial lung disease. N Engl J Med 2019; 380:2518–28.
Hoffmann-Vold A, Maher TM, Philpot EE, Ashrafzadeh A, Barake R, Barsott SI, et al. The identification and management of interstitial lung disease in systemic sclerosis: evidence-based European consensus statements. Lancet Rheumatol 2020. Published Online January 14, 2020 https://doi.org/10.1016/S2665-9913(19)30144–4.
Flaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SLF, Inoue Y, et al. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med 2019;381:1718–27.
Tzilas V, Tzouvelekis A, Bouros E, Katsaras M, Ntassiou M, Karampitsakos T, et al. Antifibrotic treatment in 18 patients with chronic hypersensitivity pneumonitis. Eur Respir J 2019;54: PA4733.
FDA News Release. FDA approves first treatment for patients with rare type of lung disease. Available at URL: https://www.fda.gov/news-events/press-announcement. Accessed on September 06, 2019.
Acharya N, Mishra D, Dhooria S, Dhir V, Jain S, Sharma S. Efficacy of pirfenidone in systemic sclerosis related interstitial lung disease –a randomized controlled trial. Ann Rheum Dis 2019;78:(Suppl. 2). Available at URL: https://ard.bmj.com/content/78/Suppl_2/200.2
